The latest price target for Mirum Pharmaceuticals (NASDAQ:MIRM) was reported by HC Wainwright & Co. on November 13, 2024. The analyst firm set a price target for $66.00 expecting MIRM to rise to within 12 months (a possible 59.04% upside). 36 analyst firms have reported ratings in the last year.

The latest analyst rating for Mirum Pharmaceuticals (NASDAQ:MIRM) was provided by HC Wainwright & Co., and Mirum Pharmaceuticals reiterated their buy rating.

There is no last upgrade for Mirum Pharmaceuticals

There is no last downgrade for Mirum Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mirum Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mirum Pharmaceuticals was filed on November 13, 2024 so you should expect the next rating to be made available sometime around November 13, 2025.

While ratings are subjective and will change, the latest Mirum Pharmaceuticals (MIRM) rating was a reiterated with a price target of $66.00 to $66.00. The current price Mirum Pharmaceuticals (MIRM) is trading at is $41.50, which is out of the analyst’s predicted range.